Our Team
Meet the people behind Oleander Medical Technologies and those who are helping us make Targeted Osmotic Lysis a reality.
Paige R. Miller, J.D.
President
Ms. Miller, a second-generation technology entrepreneur, has focused her career on leading enterprises to plan and deliver challenging, innovative projects. She served for 18 years as Commissioner of the Port of Seattle, one of the nation's largest combined airport and seaport authorities, where she was a leader in the successful effort to add the third runway at Seattle-Tacoma Airport and to transform the Seattle waterfront. She also was the founding Chair of Port Jobs, a non-profit enterprise that has connected nearly 30,000 people to jobs in the port and aviation sectors, with special focus on groups traditionally underrepresented in those fields. She has served as a board member of a privately-held real-estate development company that brought the largest mixed-use residential development to downtown Seattle, and as the Executive Director of the Arboretum Foundation, where she led the fundraising for major new exhibits and infrastructure projects. Previously she was in private law practice in Seattle and in Philadelphia.
Ms. Miller is a graduate of Brown University and of Yale Law School. She is a member of the Washington State Bar Association and serves on the board of Port Jobs. She brings the company expertise in fundraising, budgeting, critical path project management and delivery, governance, strategic partnerships, and external relations.
Dennis Paul, Ph.D.
Chief Science Officer
Dr. Paul is co-inventor with Dr. Gould of Targeted Osmotic Lysis (TOL). He is Professor of Pharmacology and Experimental Therapeutics at Louisiana State University Health Sciences Center (LSUHSC) in New Orleans.
Drs. Paul and Gould have had a research collaboration for more than 20 years. Their work initially focused on general concepts and biological principles related to the role played by sodium channels in the mechanisms responsible for pain and diabetic peripheral neuropathy. Their research on sodium channels and sodium pumps led directly to their research on manipulation of these mechanisms in the treatment of advanced cancer.
Dr. Paul's research has also contributed to the understanding of opioid pharmacology and drug-drug interactions. He received his undergraduate training at the University of Cincinnati, his Ph.D. from the University of British Columbia, and completed Post-Doctoral training at the Memorial Sloan Kettering Cancer Center. He has served on scientific advisory boards for Xanadyne Pharmaceuticals and St. Charles Pharmaceuticals.
Harry J. Gould, III, M.D., Ph.D.
Chief Medical Officer
Dr. Gould is co-inventor with Dr. Paul of Targeted Osmotic Lysis (TOL). He is Professor of Neurology and Neuroscience at LSU Health Sciences Center (LSUHSC) and has been board certified in Neurology and Pain Management. Prior to obtaining his medical degree, he was Associate Professor of Anatomy at LSUHSC and Assistant Professor of Anatomy at the University of Cincinnati.
His long research collaboration with Dr. Paul on sodium channels and pumps in neuropathic pain situations led to their discovery of the mechanisms used in the TOL treatment for advanced cancer.
Dr. Gould's early research contributed to understanding the organization of sensory/motor systems in the cerebral cortex. He received his undergraduate training at the State University of New York at Stony Brook, his Ph.D. from Brown University, and his M.D. from LSU Health Sciences Center. He has served on scientific advisory boards for Elan Pharmaceuticals, Parke-Davis, Pfizer, Ortho-McNeil Pharmaceuticals, Novartis Pharmaceuticals, Alpharma, Inc. (currently King Pharmaceuticals), Endo Pharmaceuticals, Gilead Sciences, Inc. and Depomed, Inc.
Hank Mills
Chief Business Officer
Mr. Mills has 25 years of experience as a serial entrepreneur, including taking a medical device from the “napkin stage” through development, FDA approval, Medicare code approval, marketing, launch, and successful exit. His other ventures include software development, wetlands banking, and portable storage units.
He is a graduate of Louisiana State University in finance. He has previously been a licensed stock broker and financial advisor.
His experience in fundraising, marketing, and launching products provides expertise in raising capital, creating strategic alliances, and aggressively pursuing product and commercial development.
Consultants
D. Bruce Burlington, M.D.
Dr. Burlington served as the director of the Device and Radiological Health Center of the U.S. Food and Drug Administration for six years (1993-99). Subsequently, he was an Executive Vice President of Wyeth. He received his M.D. from LSU Health Sciences Center. Dr. Burlington advises OMT on the regulatory path through the medical side of the FDA.
Robert P. Hunter, Ph.D.
Dr. Hunter is a specialist in FDA regulatory processes for animal health. He has advised or worked with leading companies in the field including Elanco, Pfizer, Parnell, and Provetica. He received his Ph.D. from LSU College of Veterinary Medicine specializing in Veterinary Pharmacology. He advises OMT on the regulations related to new devices for animal health and on providers for animal clinical trials.
Carol R. Scheman
Ms. Scheman is a former deputy commissioner of the U.S. Food and Drug Administration (1991-94) and managed external affairs as vice president of the Association of American Universities (AAU), Northeastern University, The Uniformed Services University (USU) of the Health Sciences, and the University of Pennsylvania. She is an independent consultant working with the federal government, research universities and scientific societies.
Collaborators
The Phantom Laboratory
The Phantom Laboratory manufactures the coaxial pulsed electric field device used to provide the stimulation in the TOL process.
Metairie Small Animal Hospital
Led by Dr. Brian Melius, DVM, the staff at Metairie Small Animal Hospital has worked with Oleander to diagnose and treat dogs and cats with advanced cancer since 2020.
Monroe Street Animal Hospital
Led by veterinarians Dr. Alissa Whitney and Dr. Paige Massey, the Monroe Street team has worked with Oleander since 2021 to diagnose and treat dogs and cats with cancer.
